Clinical Trial Update: Validation of KELIM as a Predictive/Prognostic Factor for Maintenance Treatment With iPARP in First-Line Ovarian Cancer

View source ↗

Summary

A clinical trial update focusing on validating the KELIM metric as a predictive and prognostic biomarker for maintenance PARP inhibitor therapy in first-line ov…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• PARP inhibitor (iPARP) (PARP inhibitor)

Snippet

Sponsor: ARCAGY/ GINECO GROUP | Conditions: Ovarian Cancer | Status: RECRUITING